Volasertib, a Potential New Treatment for Rhabdomyosarcoma, Receives Orphan Drug Designation from the U.S. FDA
Oncoheroes Biosciences, a biotech focused on advancing new therapies for childhood cancer, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) to volasertib for its use in treating pediatric rhabdomyosarcoma and other rare soft tissue sarcomas. Key... - October 15, 2020
FDA Grants Rare Pediatric Disease Designation (RPDD) to Volasertib for Rhabdomyosarcoma
Oncoheroes Biosciences, a biotech focused on advancing new therapies for childhood cancer, is pleased to announce that the United States Food and Drug Administration (FDA) has granted the designation of rare pediatric disease to volasertib, an investigational treatment for rhabdomyosarcoma. Key... - September 25, 2020
Oncoheroes Biosciences Inc. and Boehringer Ingelheim International GmbH Sign Exclusive Licensing Agreement for Volasertib
Oncoheroes Biosciences Inc (“Oncoheroes”) and Boehringer Ingelheim International GmbH (“Boehringer Ingelheim”) have signed a worldwide, exclusive licensing agreement for volasertib, an investigational anti-cancer compound that was originally discovered and developed by... - September 19, 2019